SCI Pharmtech Inc
TWSE:4119
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
86.4
100
|
| Price Target |
|
We'll email you a reminder when the closing price reaches TWD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
SCI Pharmtech Inc
Current Portion of Long-Term Debt
SCI Pharmtech Inc
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Current Portion of Long-Term Debt
NT$129.1m
|
CAGR 3-Years
328%
|
CAGR 5-Years
134%
|
CAGR 10-Years
N/A
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Current Portion of Long-Term Debt
NT$91.3m
|
CAGR 3-Years
40%
|
CAGR 5-Years
43%
|
CAGR 10-Years
20%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Current Portion of Long-Term Debt
NT$480.8m
|
CAGR 3-Years
16%
|
CAGR 5-Years
11%
|
CAGR 10-Years
6%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Current Portion of Long-Term Debt
NT$18.6m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Current Portion of Long-Term Debt
NT$1.4B
|
CAGR 3-Years
30%
|
CAGR 5-Years
39%
|
CAGR 10-Years
32%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Current Portion of Long-Term Debt
NT$83.4m
|
CAGR 3-Years
64%
|
CAGR 5-Years
21%
|
CAGR 10-Years
-2%
|
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
What is SCI Pharmtech Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
129.1m
TWD
Based on the financial report for Jun 30, 2024, SCI Pharmtech Inc's Current Portion of Long-Term Debt amounts to 129.1m TWD.
What is SCI Pharmtech Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
134%
Over the last year, the Current Portion of Long-Term Debt growth was 8 402%. The average annual Current Portion of Long-Term Debt growth rates for SCI Pharmtech Inc have been 328% over the past three years , 134% over the past five years .
You don't have any saved screeners yet
